The pharmaceutical industry is facing a growing challenge. Nearly 70% to 90% of new drug candidates have poor water solubility, making it difficult for medicines to dissolve properly and reach the bloodstream.
This is where Hot Melt Extrusion (HME) has become a game-changing technology. By converting poorly soluble drugs into amorphous solid dispersions, HME can significantly improve bioavailability, helping medicines work more effectively while reducing formulation challenges.
Today, many pharmaceutical companies are partnering with specialized Contract Development and Manufacturing Organizations (CDMOs) that offer HME services from early clinical development through full commercial manufacturing.
According to industry estimates, more than half of small-molecule drug candidates currently in development face solubility-related issues, driving increased adoption of HME-based drug delivery technologies.
The Growing Demand for Clinical-to-Commercial HME Partners
Drug developers no longer want separate vendors for formulation development, clinical supplies, process scale-up, and commercial manufacturing.
Instead, they seek a single CDMO partner capable of supporting the entire product lifecycle.
The advantages are clear:
- Faster technology transfer
- Lower development costs
- Reduced regulatory risk
- Faster commercialization timelines
- Greater process consistency
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to encourage advanced manufacturing technologies and continuous manufacturing approaches, both of which align closely with HME processes.
Leading CDMOs in Hot Melt Extrusion
Several organizations have established themselves as leaders in HME development and manufacturing.
AbbVie Contract Manufacturing
AbbVie is widely regarded as one of the most experienced HME service providers globally.
The company has over 35 years of hot melt extrusion experience and has developed more than 100 HME-based products. It has also commercialized over 10 HME products worldwide.
AbbVie operates a network of more than 10 extruders ranging from 18 mm to 70 mm screw sizes, supporting everything from early clinical batches to large-scale commercial production.
Its integrated capabilities include formulation development, clinical manufacturing, scale-up, validation, packaging, and commercial supply.
Catalent
Catalent’s OptiMelt® platform has become a major solution for pharmaceutical companies developing poorly soluble compounds.
The company provides pilot-scale, development-scale, and commercial-scale extrusion capabilities across multiple global facilities.
One of Catalent’s strengths is the integration of downstream manufacturing technologies, allowing extruded materials to be converted directly into tablets, capsules, and controlled-release formulations.
This significantly reduces development complexity for sponsors.
Midas Pharma
Midas Pharma specializes in hot melt extrusion for high-potency compounds and challenging formulations.
The company offers end-to-end development services, including formulation screening, process optimization, registration batches, and commercial manufacturing.
Its facilities maintain multiple international GMP certifications, supporting global regulatory submissions.
Specialized Emerging Providers
A growing number of specialized HME-focused organizations are also entering the market.
Companies such as Schenergix and Swalava are expanding capabilities in pilot and commercial-scale extrusion, offering flexible solutions for pharmaceutical, nutraceutical, and specialty drug developers.
These providers are helping increase global HME manufacturing capacity while supporting smaller and mid-sized pharmaceutical innovators.
Market Snapshot
| Metric | Industry Data |
|---|---|
| Poorly soluble drug candidates in development | 70–90% |
| AbbVie HME experience | 35+ years |
| AbbVie products developed | 100+ |
| AbbVie commercial HME launches | 10+ |
| AbbVie extrusion network | 10+ extruders |
| Commercial extruder sizes available | 18 mm – 70 mm |
| Catalent HME facilities | 3 global sites |
| Scale-up range supported by specialized providers | Up to 200 kg/hr |
What Makes an HME CDMO Truly Commercial Ready?
Selecting an HME partner involves much more than having extrusion equipment.
The strongest CDMOs provide formulation expertise, Quality-by-Design (QbD) methodologies, regulatory support, process analytical technologies, and proven scale-up experience.
A successful clinical formulation can fail commercially if the process cannot be reproduced consistently at larger volumes.
Therefore, companies should evaluate a CDMO’s commercial launch history, regulatory inspection record, manufacturing network, and technical expertise before making a selection.
The Future of Hot Melt Extrusion Manufacturing
As pharmaceutical pipelines continue shifting toward complex and poorly soluble molecules, demand for hot melt extrusion services is expected to rise steadily.
The technology’s ability to improve bioavailability, eliminate solvents, enable continuous manufacturing, and support scalable production makes it one of the most attractive formulation platforms available today.
For drug developers seeking a seamless path from clinical development to commercialization, experienced HME CDMOs such as AbbVie, Catalent, and Midas Pharma are increasingly becoming strategic partners rather than simple manufacturing vendors.
The result is faster development, lower risk, and ultimately better medicines reaching patients worldwide.
Get Easy Access
Access our exclusive, data-rich dashboard dedicated to the life science industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting which is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium